IPX 232
Alternative Names: IPX-232Latest Information Update: 15 May 2018
Price :
$50 *
At a glance
- Originator Impax Pharmaceuticals
- Class Antimigraines
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Migraine
Most Recent Events
- 07 May 2018 Amneal Pharmaceuticals and Impax Laboratories completed their business combination to form Amneal Pharmaceuticals
- 01 Aug 2014 IPX 232 is available for licensing as of 01 Aug 2014. http://www.impaxlabs.com/our_company/future_directions
- 07 Oct 2013 Phase-I clinical trials in Migraine in USA (unspecified route)